Filing Flows › ImmunityBio (IBRX) › Q1 2026 › vs Q4 2025
ImmunityBio (IBRX) Q1 2026 vs Q4 2025 (quarter over quarter)
ImmunityBio's revenue rose $5.9M (+15%) from $38.3M in Q4 2025 to $44.2M in Q1 2026. The biggest changes: Product revenue, net +$5.9M (+15%); Other revenues +$26K (+200%).
ImmunityBio, Q1 2026: revenue $44.2M (+168% year over year), operating margin -157.9%, net loss $633M, operating cash flow −$75.4M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $44.2M | $38.3M | $5.9M | +15% |
| Other revenues | $39K | $13K | $26K | +200% |
| Revenue | $44.2M | $38.3M | $5.9M | +15% |
| Net loss | $633M | $62.0M | $571M | +921% |
| Costs & expenses | $677M | $103M | $574M | +557% |
| Operating costs | $114M | $103M | $11.0M | +11% |
| Interest & other, net | $563M | −$2.6M | $566M | — |
| Income tax | $9K | −$135K | $144K | — |
| Cost of revenue | $238K | $382K | −$144K | -38% |
| Other operating costs | $114M | $103M | $11.2M | +11% |
| Operating cash sources | $633M | $62.0M | $571M | +921% |
| Depreciation & amortization | $4.4M | $3.9M | $515K | +13% |
| Share-based compensation | $8.2M | $8.7M | −$577K | -7% |
| Working capital & other | $545M | −$21.0M | $566M | — |
| Cash used in operations | $75.4M | $70.4M | $5.0M | +7% |
| Net loss absorbed | $633M | $62.0M | $571M | +921% |
Questions
How much did ImmunityBio's revenue grow quarter over quarter in Q1 2026?
ImmunityBio's revenue rose $5.9M (+15%) from $38.3M in Q4 2025 to $44.2M in Q1 2026.
What drove ImmunityBio's revenue change in Q1 2026?
Product revenue, net +$5.9M (+15%); Other revenues +$26K (+200%).